SOUTH SAN FRANCISCO, Calif. — May 6, 2026 — Leads & Copy — Cytokinetics, Incorporated (Nasdaq: CYTK) has announced the pricing of its underwritten public offering of 9,859,155 shares of common stock at $71.00 per share, before underwriting discounts and commissions.
The offering is expected to generate gross proceeds of approximately $700 million for Cytokinetics before deducting underwriting discounts, commissions, and other offering expenses. The company anticipates the offering to close on May 8, 2026, contingent upon standard closing conditions.
Underwriters have been granted a 30-day option to purchase up to an additional 1,478,873 shares of Cytokinetics’ common stock at the public offering price, less underwriting discounts and commissions. All shares in the offering will be sold by Cytokinetics.
Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, and Jefferies are serving as joint book-running managers for the offering. Mizuho is the lead co-manager, while Citizens Capital Markets, Needham & Company, B. Riley Securities, and H.C. Wainwright & Co. are co-managers.
Cytokinetics has filed a shelf registration statement, including a base prospectus, with the SEC, which became automatically effective. A preliminary prospectus supplement and accompanying prospectus related to the offering have been filed. A final prospectus supplement and accompanying prospectus will be filed with the SEC and made available on the SEC’s website.
Copies of the final prospectus supplement and accompanying prospectus, when available, can be obtained from Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, or Jefferies LLC.
This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of these securities in any jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Cytokinetics, a specialty cardiovascular biopharmaceutical company, leverages over 25 years of scientific innovation in muscle biology to advance potential new medicines for cardiac muscle dysfunction. MYQORZO® (aficamten), a cardiac myosin inhibitor, is approved in the U.S., Europe, and China for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for heart failure with severely reduced ejection fraction, and ulacamten, an investigational cardiac myosin inhibitor for heart failure with preserved ejection fraction.
The company has issued forward-looking statements regarding the completion of the offering, which are subject to risks and uncertainties. Cytokinetics disclaims any obligation to update these statements. Risks and uncertainties related to market conditions and the satisfaction of customary closing conditions could impact the completion of the public offering. Additional information can be found in Cytokinetics’ filings with the SEC.
Source: Cytokinetics, Incorporated
